ISSN: 2167-0501
Biochemistry & Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Acetaminophen/Autism: Alarm?

Amany A. Abdin*
Department of Pharmacology, Faculty of Medicine, Tanta University, Egypt
Corresponding Author : Amany A. Abdin
Department of Pharmacology
Faculty of Medicine
Tanta University, Egypt
Tel: +2-01223700963
E-mail: amanyabdin@med.tanta.edu.eg
Received December 12, 2013; Accepted December 14, 2013; Published December 23, 2013
Citation: Abdin AA (2013) Acetaminophen/Autism: Alarm?. Biochem Pharmacol (Los Angel) 2:e148. doi:10.4172/2167-0501.1000e148
Copyright: © 2013 Abdin AA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Biochemistry & Pharmacology: Open Access

Keywords
Acetaminophen; Autism; N-acetylp-benzoquinoneimine (NAPQI)
Autism is a developmental disorder defined by social and communication deficits and ritualistic-repetitive behaviors that appear in early childhood [1]
Autism is complex and heterogeneous in origin and proposed to be due to interaction of genetic and environmental factors [2]. The incidence of autism has risen ~10-fold since the early 1980s, with most of this rise not explainable by changing diagnostic criteria. Is there any explanation for that? Clinical and epidemiological studies and post-market pharmacovigilence are of utmost importance in detection of unrecognized or missed drug-induced side effects. Acetaminophen (paracetamol) is a widely used over-the-counter (OTC) analgesic and antipyretic that was introduced since 1955 [3]. Unfortunately the recent mechanistic evidence suggests correlation between acetaminophen exposure and increased incidence and risk of autism [4-6]. Considerable evidence supports this contention, most notably the exponential chronological rise in acetaminophen consumption for infants and young children since 1980s when it began to replace aspirin [7]. For instance, this compound has been taken, at least once, by more than 85% of children under the age of 91 months in the UK [8]. Children who are poor metabolizrs of acetaminophen may be at higher risk even under therapeutic doses [5]. There are four 2major pathways for acetaminophen detoxification namely; the major pathways of glucuronidation or deacetylation to a phenol, and sulfation catalyzed by phenolsulfotransferase, and the minor toxic pathway by the cytochrome P450 (CYP2E1) enzyme producing N-acetylpbenzoquinone imine (NAPQI) Glucuronidation is commonly present at low capacity in the fetus, newborns, and young infants, such that exposure to acetaminophen at these times leads to greater metabolism by other pathways [9]. One key piece of evidence came from the observation that sulfation pathway catalyzed by phenolsulfotransferase is proved to be deficient in autism. This leads to overproduction of the toxic metabolite NAPQI from acetaminophen with a subsequent depletion of glutathione the main source of sulfhydryl groups with reduction in the ability to detoxify a host of toxic chemicals in the environment, increasing oxidative stress, which leads to protein, lipid, and nucleic acid damage from free radicals [5]. The characteristic loss of Purkinje cells in the brains of autistic cases is consistent with depletion of brain glutathione and as of 2012; there are many articles that indicated an association between toxic chemical exposure and autism. For example, exposure to NAPQI derived from acetaminophen, competitively inhibits the reaction of metals (such as mercury) with the sulfhydryl groups in children with autism [10]. Importantly, NAPQI also inhibits the isomerase and the biological activities of macrophage migration inhibitory factor (MIF) [11]. Polymorphism of MIF has recently been associated with autism spectrum disorders (ASDs) [8]. In addition, oxidative damage of mitochondrial proteins and DNA by acetaminophen leads to activation of DNase (s) which is typically responsible for nuclear DNA fragmentation and apoptosis [12]. There are several studies had shown an association between mitochondrial dysfunction and apoptosis with autism [13]. Also, cetaminophen has been found to induce apoptosis-dependent neurotoxicity by increasing neuronal CYP2E1 enzymatic activity, leading to neuronal death through mitochondrial mediated mechanisms that involve cytochrome c release and caspase-3 activation. One of the prominent features of autism is immune system dis-ccregulation [14]. Recently, acetaminophen has been postulated to provoke autism through neuroimmunomodulatory effect that may be mediated by activation of endocannabinoids system. Acetaminophen metabolite p-aminophenol can conjugate with arachidonic acid in the brain and spinal cord resulting in inhibition of the cellular uptake of anandamide, a naturally occurring endocannabinoid [15]. The cannabinoid CB2 receptors are primarily located in immune tissues and cells and may serve a regulatory function [16]. To this point of information, safety of acetaminophen becomes questionable and acetaminophen/autism alarm should be paid more attention.
References
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11252
  • [From(publication date):
    December-2013 - Oct 02, 2016]
  • Breakdown by view type
  • HTML page views : 7514
  • PDF downloads :3738
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version